ACTU (Actuate Therapeutics) 3-Year Book Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $0.99
View Full Analysis

What is Actuate Therapeutics 3-Year Book Growth Rate?

Actuate Therapeutics ACTU -1.98% 14 3-Year Book Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 1,132 Biotechnology companies, Actuate Therapeutics ranks worse than 88339.13% on this metric.

Actuate Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was $0.04.

During the past 12 months, Actuate Therapeutics's average Book Value per Share Growth Rate was 6720.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Actuate Therapeutics  (NAS:ACTU) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Actuate Therapeutics 3-Year Book Growth Rate Related Terms

ACTU vs KYNB, IGC, PLRZ: 3-Year Book Growth Rate Comparison

For the Biotechnology subindustry, Actuate Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's 3-Year Book Growth Rate falls into.


ACTU
14GF Score
Actuate Therapeutics Inc ACTU
3-Year Book Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of 0.00% mean?
Actuate Therapeutics (ACTU) has a 3-Year Book Growth Rate of 0.00% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Actuate Therapeutics and its competitors. According to the industry distribution chart, Actuate Therapeutics ranks #999999 out of 1132 companies in the Biotechnology industry.
Is Actuate Therapeutics' 3-Year Book Growth Rate too high?
Actuate Therapeutics' current 3-Year Book Growth Rate is 0.00%. Based on the distribution chart, Actuate Therapeutics ranks #999999 out of 1132 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' 3-Year Book Growth Rate compare to KYNB and IGC?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #999999 out of 1132 companies for 3-Year Book Growth Rate. This places Actuate Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Actuate Therapeutics and its competitors. Actuate Therapeutics's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current 3-Year Book Growth Rate of 0.00%. The current 3-Year Book Growth Rate is 0.00%. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current 3-Year Book Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.99
Price